Product Images Pemetrexed

This is a description of Pemetrexed for Injection USP, which is a sterile, nonpyrogenic, preservative-free drug prescribed for intravenous use only. It comes in a single-dose vial with 100 mg of Pemetrexed as an active ingredient, and the drug needs to be reconstituted before use by adding 2L of 0.9% Sodium to make a solution containing 25 mg/mL_pemetrexed. The reconstituted solution must be used within 24 hours of initial reconstitution, and any unused portion must be discarded. The storage temperature for the drug is 2°-8°C (36°-46°F), and it is a cytotoxic agent. The recommended dosage of this drug is not available in the provided text.*

This is a product description for an injectable drug called Pemetrexed, which comes in vials containing 500mg of the drug. It includes information on how to reconstitute the drug for use, dosage and administration directions, as well as storage requirements. The drug is a cytotoxic agent and is for intravenous use only. The manufacturer is Nl Pharmaceuticals.*

Pemetrexed is an injection used intravenously. The remaining text is not clear or not available.*

The text describes a graph showing the overall survival percentage over time in months for two types of chemotherapy treatments: A+P+C (which includes pemetrexed, pembrolizumab, and platinum chemotherapy) and A+C (which includes pemetrexed, platinum chemotherapy, and a placebo). The number at risk is also shown for each month.*

The text describes a graph showing the survival probability of two groups, "Pemeveies" and "Placebo," over time in months. The number of patients at risk is also shown for each month.*

The text is presenting a graph that compares the survival probability of two treatments: "Pemetrexed+Ciplain" and "Gemcitabine+Cpltin". The survival time is measured in months and it ranges from 0 to 88 months. The graph shows the percentage of patients surviving at each stage of the treatment for both options.*

This appears to be a chart showing the Survival Probability of patients at risk, divided between those who received "Pematesed" (441 patients) and those who received a placebo (222 patients). The chart also shows Survival Time in months. However, without context or further information, it is not clear what the specific study or medical condition being analyzed is.*

This is a table for survival probability and patients at risk, comparing two groups: pemeexed and placebo. The table also shows survival times in months. Unfortunately, the text is not clear and seems to contain some errors due to recognition.*

This appears to be a table displaying survival probability based on survival time (measured in months) for two groups of patients: those who received "Pemevexsd" (which may refer to a medication or treatment) and those who received a placebo. The number of patients at risk decreases as time goes on for both groups. Without additional context, it is difficult to draw further conclusions or offer more specific insights.*

This text appears to be part of a medical or clinical study. It includes information about two treatments (Pemetred and Cisplatin) and the number of patients at risk for each treatment over a period of several months. The "Survival Probability" heading suggests that this information is related to the likelihood of patients surviving while receiving these treatments. However, since the text is incomplete and appears to be a table or graph, additional context would be needed to provide a more specific and accurate description.*